Premysl Bercik

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1776388/publications.pdf

Version: 2024-02-01

75 papers	9,676 citations	87401 40 h-index	93651 72 g-index
76 all docs	76 docs citations	76 times ranked	12872 citing authors

#	Article	IF	Citations
1	Purinergic Pathways in the Spinal Microglia as a Putative Target for Treatment of Chronic Abdominal Pain. Cellular and Molecular Gastroenterology and Hepatology, 2022, , .	2.3	0
2	Longâ€term personalized low FODMAP diet in IBS. Neurogastroenterology and Motility, 2022, 34, e14356.	1.6	11
3	Gluten-Free Diet Reduces Symptoms, Particularly Diarrhea, in Patients With Irritable Bowel Syndrome and AntigliadinÂIgG. Clinical Gastroenterology and Hepatology, 2021, 19, 2343-2352.e8.	2.4	30
4	Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis. Gastroenterology, 2021, 160, 1532-1545.	0.6	94
5	Saccharomyces boulardii CNCM Iâ€745 modulates the microbiotaâ€“gutâ€“brain axis in a humanized mouse model of Irritable Bowel Syndrome. Neurogastroenterology and Motility, 2021, 33, e13985.	1.6	20
6	Transcriptional markers of excitation-inhibition balance in germ-free mice show region-specific dysregulation and rescue after bacterial colonization. Journal of Psychiatric Research, 2021, 135, 248-255.	1.5	9
7	Fecal microbiome differs between patients with systemic sclerosis with and without small intestinal bacterial overgrowth. Journal of Scleroderma and Related Disorders, 2021, 6, 290-298.	1.0	8
8	Gut Microbiome and Its Role in the Pathophysiology of Irritable Bowel Syndrome. Acta Gastroenterologica Latinoamericana, 2021, 51, .	0.0	0
9	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. Alimentary Pharmacology and Therapeutics, 2021, 53, 253-264.	1.9	8
10	Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts. Neuropsychobiology, 2020, 79, 5-12.	0.9	11
11	Probiotics for Celiac Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2020, 115, 1584-1595.	0.2	40
12	Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Science Translational Medicine, 2020, 12, .	5.8	98
13	Spotlight: Probiotics Guidelines. Gastroenterology, 2020, 159, 707.	0.6	3
14	Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. Diabetes Care, 2020, 43, 1553-1556.	4.3	19
15	Application of metabolomics to the study of irritable bowel syndrome. Neurogastroenterology and Motility, 2020, 32, e13884.	1.6	12
16	Association Between Inflammatory Bowel Diseases and Celiac Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 159, 884-903.e31.	0.6	54
17	AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology, 2020, 159, 697-705.	0.6	209
18	Evidence-based and mechanistic insights into exclusion diets for IBS. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 406-413.	8.2	46

#	Article	IF	Citations
19	The Brain-Gut-Microbiome Axis and Irritable Bowel Syndrome. Gastroenterology and Hepatology, 2020, 16, 322-324.	0.2	1
20	Higher prevalence of irritable bowel syndrome and greater gastrointestinal symptoms in obsessive-compulsive disorder. Journal of Psychiatric Research, 2019, 118, 1-6.	1.5	22
21	Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Alimentary Pharmacology and Therapeutics, 2019, 49, 723-732.	1.9	37
22	Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients. Metabolomics, 2019, 15, 82.	1.4	32
23	Lactobacilli Degrade Wheat Amylase Trypsin Inhibitors to Reduce Intestinal Dysfunction Induced by Immunogenic Wheat Proteins. Gastroenterology, 2019, 156, 2266-2280.	0.6	97
24	Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2. Nature Communications, 2019, 10, 1198.	5.8	102
25	Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission â€“ confounded by the gut microbiome? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1088-1089.	1.9	0
26	Small-Molecule Allosteric Triggers of Clostridium difficile Toxin B Auto-proteolysis as a Therapeutic Strategy. Cell Chemical Biology, 2019, 26, 17-26.e13.	2.5	11
27	Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology, 2019, 156, 46-58.e7.	0.6	162
28	Reply. Gastroenterology, 2018, 154, 764-765.	0.6	0
29	High salt diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production. Microbiome, 2018, 6, 57.	4.9	176
30	Su1658 - Gut Microbiota Defines Host Responses to Dietary Fermentable Carbohydrates in IBS: The Role of Bacterial Histamine. Gastroenterology, 2018, 154, S-565.	0.6	1
31	916 - Gut Microbiota-Diet Interactions in a Humanized Mouse Model of IBS: The Role of Intestinal Mast Cells. Gastroenterology, 2018, 154, S-182.	0.6	2
32	Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia. Scandinavian Journal of Gastroenterology, 2017, 52, 396-402.	0.6	3
33	Proton pump inhibitors for functional dyspepsia. The Cochrane Library, 2017, 3, CD011194.	1.5	40
34	Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Science Translational Medicine, 2017, 9, .	5.8	366
35	FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut, 2017, 66, 1241-1251.	6.1	330
36	Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies. Gastroenterology, 2017, 153, 395-409.e3.	0.6	90

#	Article	IF	Citations
37	Diet-Microbiota Interactions Underlie Symptoms' Generation in IBS. Gastroenterology, 2017, 152, S160.	0.6	2
38	Impact ofÎ²2-1 fructan on faecal community change: results from a placebo-controlled, randomised, double-blinded, cross-over study in healthy adults. British Journal of Nutrition, 2017, 118, 441-453.	1.2	18
39	Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology, 2017, 153, 448-459.e8.	0.6	542
40	Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling. Genome Medicine, 2016, 8, 72.	3.6	150
41	Gluten Introduction to Infant Feeding and Risk of Celiac Disease: Systematic Review and Meta-Analysis. Journal of Pediatrics, 2016, 168, 132-143.e3.	0.9	47
42	Lost in Translation: The Gut Microbiota in Psychiatric Illness. Canadian Journal of Psychiatry, 2015, 60, 460-463.	0.9	17
43	Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. American Journal of Gastroenterology, 2015, 110, 1038-1048.	0.2	108
44	Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiology, 2015, 15, 67.	1.3	208
45	Lack of Utility of Symptoms and Signs at First Presentation as Predictors of Inflammatory Bowel Disease in Secondary Care. American Journal of Gastroenterology, 2015, 110, 716-724.	0.2	16
46	The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes, 2014, 5, 419-429.	4.3	112
47	The origin of segmentation motor activity in the intestine. Nature Communications, 2014, 5, 3326.	5.8	155
48	The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models. Inflammatory Bowel Diseases, 2014, 20, 417-430.	0.9	204
49	The Rome III Criteria for the Diagnosis of Functional Dyspepsia in Secondary Care Are Not Superior to Previous Definitions. Gastroenterology, 2014, 146, 932-940.e1.	0.6	71
50	The Effects of Inflammation, Infection and Antibiotics on the Microbiota-Gut-Brain Axis. Advances in Experimental Medicine and Biology, 2014, 817, 279-289.	0.8	73
51	The microbiotaâ€“gutâ€“brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both?. Journal of Physiology, 2014, 592, 2989-2997.	1.3	242
52	Validation of the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care. Gastroenterology, 2013, 145, 1262-1270.e1.	0.6	163
53	The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Current Opinion in Microbiology, 2013, 16, 240-245.	2.3	180
54	ILSI Brazil International Workshop on Functional Foods: a narrative review of the scientific evidence in the area of carbohydrates, microbiome, and health. Food and Nutrition Research, 2013, 57, 19214.	1.2	16

#	Article	IF	Citations
55	The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes, 2013, 4, 17-27.	4.3	194
56	Targeting the microbiotaâ€“gutâ€“brain axis to modulate behavior: Which bacterial strain will translate best to humans?. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E174; author reply E176.	3.3	25
57	The interplay between the intestinal microbiota and the brain. Nature Reviews Microbiology, 2012, 10, 735-742.	13.6	1,249
58	Su1990 The Role of Microbiota in the Maternal Separation Model of Depression. Gastroenterology, 2012, 142, S-554.	0.6	3
59	The Intestinal Microbiota Affect Central Levels of Brain-Derived Neurotropic Factor and Behavior in Mice. Gastroenterology, 2011, 141, 599-609.e3.	0.6	1,380
60	Epidemiology and Burden of Chronic Constipation. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 11B-15B.	1.8	39
61	The microbiota-gut-brain axis: learning from intestinal bacteria?. Gut, 2011, 60, 288-289.	6.1	66
62	Chronic Gastrointestinal Inflammation Induces Anxiety-Like Behavior and Alters Central Nervous System Biochemistry in Mice. Gastroenterology, 2010, 139, 2102-2112.e1.	0.6	553
63	Pathogenic Factors Involved in the Development of Irritable Bowel Syndrome: Focus on a Microbial Role. Infectious Disease Clinics of North America, 2010, 24, 961-975.	1.9	28
64	Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 296, R587-R594.	0.9	55
65	Review: Effect of probiotics on gastrointestinal function: evidence from animal models. Therapeutic Advances in Gastroenterology, 2009, 2, S31-S35.	1.4	21
66	Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism. Science, 2009, 325, 617-620.	6.0	443
67	The role of luminal factors in the recovery of gastric function and behavioral changes after chronicHelicobacter pyloriinfection. American Journal of Physiology - Renal Physiology, 2008, 295, G664-G670.	1.6	44
68	Antidepressants Attenuate Increased Susceptibility to Colitis in a Murine Model of Depression. Gastroenterology, 2006, 130, 1743-1753.	0.6	111
69	Is Irritable Bowel Syndrome a Low-Grade Inflammatory Bowel Disease?. Gastroenterology Clinics of North America, 2005, 34, 235-245.	1.0	165
70	Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology, 2004, 127, 179-187.	0.6	407
71	Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology, 2004, 127, 826-837.	0.6	171
72	Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. Gastroenterology, 2002, 123, 1205-1215.	0.6	68

#	Article	IF	Citations
73	In Vivo motility disturbances in a model of post-infective IBS. Gastroenterology, 2001, 120, A71.	0.6	2
74	Interstitial cells of Cajal and inflammation-induced motor dysfunction in the mouse small intestine. Gastroenterology, 2000, 119, 1590-1599.	0.6	132
75	Quantitative analysis of intestinal motor patterns: Spatiotemporal organization of nonneural pacemaker sites in the rat ileum. Gastroenterology, 2000, 119, 386-394.	0.6	51